Highlights Chimerix, Inc.

Equities

CMRX

US16934W1062

Delayed Nasdaq Other stock markets 02:48:29 2024-04-29 pm EDT			5-day change	1st Jan Change
0.9211 ^USD	+2.36%		+0.79%	-4.30%

Mar. 21	Chimerix Appoints Marc D. Kozin to Board of Directors	CI
Feb. 29	Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000	Feb. 29	MT
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000	Nov. 02	MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery	23-08-16	CI
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000	23-08-03	MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (CMRX) CHIMERIX Reports Q1 Revenue $283,000, vs. Street Est of $130,000	23-05-04	MT
Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Earnings Flash (CMRX) CHIMERIX Posts Q4 Revenue $814,000, vs. Street Est of $580,000	23-03-02	MT
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-02	CI
Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study	22-12-08	CI
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (CMRX) CHIMERIX Reports Q3 Revenue $32.6M	22-11-03	MT
Emergent BioSolutions Completes Acquisition of Rights to Smallpox Oral Antiviral Tembexa	22-09-26	MT
Emergent BioSolutions Inc. completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. for approximately $370 million.	22-09-25	CI
Chimerix Chief Business Officer Michael Andriole Executes Purchase of 50,000 Shares	22-08-29	MT
Chimerix Wins BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox	22-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Chimerix, Inc.

Equities

CMRX

US16934W1062

Highlights

Filters